Meeting Banner
Abstract #1510

Quantitative Evaluation of Impaired Neuroenergetics in Parkinson’s Disease and the Treatment Effects of Ursodeoxycholic Acid

Xiao-Hong Zhu1, Byeong-Yuel Lee1, Lisa Coles2, Abhishek G Sathe2, Paul Tuite3, Jim Cloyd2, Walter Low4, Clifford J. Steer5, Chi Chen6, and Wei Chen1
1CMRR, Department of Radiology, University of Minnesota, Minneapolis, MN, United States, 2Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, United States, 3Department of Neurology, University of Minnesota, Minneapolis, MN, United States, 4Department of Neurosurgery, University of Minnesota, Minneapolis, MN, United States, 5Departments of Medicine and Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, United States, 6Department of Food Science and Nutrition, University of Minnesota, Minneapolis, MN, United States

Abnormal energy metabolism due to mitochondrial dysfunction is thought to be a major contributor to the progression of Parkinson’s disease (PD). We employed 31P MRS-MT technique at 7T to quantify key bioenergetic parameters in the occipital lobe of people with PD (PWPs). Significantly lower intracellular ATP concentrations together with elevated ATPase activity was found in PWPs; suggesting that augmented ATPase enzymatic activity may represent a compensatory mechanism to bioenergetic deficits that occur in PD. The FDA-approved drug, ursodeoxycholic acid (UDCA), shown to have energy-enhancing properties was evaluated for its effect on improving neuroenergetics in PWPs using the 31P MRS-MT approach.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here